Abvance Therapeutics

People living with type 1 diabetes (T1D) require insulin to manage their blood sugar levels. One challenge with current insulin therapies is that the exact amount required is variable. Too much insulin can cause low blood sugar or hypoglycemia, a serious complication that can result in seizures, comas, or death. When patients experience life-threatening hypoglycemia, glucagon is an additional drug that can be given to raise their blood sugar levels. Out of fear of a hypoglycemic event, people living with T1D sometimes underdose their insulin which can then cause their blood sugar to run too high. Helmsley is committed to improving the lives of people living with T1D, and we support the development of novel therapies that reduce the occurrence of hypoglycemia. Abvance Therapeutics is working on a novel therapy, ABV100, that combines both rapid-acting insulin and glucagon in a simultaneous delivery that allows for better control of blood sugar levels. The drug avoids the dangerous effects of hypoglycemia by preventing it at the point of administration. Read more about our program related investment with Abvance Therapeutics: https://lnkd.in/es35_Vtn #Type1Diabetes #T1D #Hypoglycemia #DiabetesAwarenessMonth

If you missed the Abvance Therapeutics KOL Event, the 60 minute replay is available through our friends at LifeSci Events. Watch the replay here —> https://lnkd.in/eNC7U6Mm #hypoglycemia #T1D #insulin #glucagon

For those of you who were not able to attend, here is a replay of our KOL Event with Katie Ellias, Steven R. Smith, MD, Carol Wysham, MD, and Sean Sullivan, PhD from September 26, 2024. Thank you for watching. https://lnkd.in/gGGaX2Xk

Thank you, Katie Ellias! Very. much looking forward to seeing you and our panelists Steven R. Smith, MD, Carol Wysham, Sean Sullivan, and David Maggs on Thursday 26 September at 10A eastern. Details and registration information can be found here: https://lnkd.in/gGGaX2Xk

Announcing a KOL Virtual Event on the Promise of a Transformative Insulin-Glucagon Combination in the Treatment of Insulin-Requiring Diabetes. Please join us on September 26 at 10AM eastern. The event, moderated by Katie Ellias, will feature our CEO and co-founder David Maggs, MD along with panelists Steven R. Smith, MD, Sean Sullivan, PhD, and Carol Wysham, MD. For information and to register, please click here: https://bit.ly/4cZ30W2

Abvance is pleased to announce a $3.9 million program related investment from The Helmsley Charitable Trust in support of our work to address the burden of hypoglycemia. https://lnkd.in/eYgtftQV